NICE plans appraisal for Pfizer's Inlyta in RCC where others have failed
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, wants to look at Pfizer's Inlyta (axitinib) for treating advanced renal cell carcinoma (RCC) after prior systematic treatment has failed. The drug could face a rocky ride if previous NICE appraisals for second-line RCC options are anything to go by. The institute has so far turned down Bayer's Nexavar (sorafenib), Pfizer's Sutent (sunitinib) and Novartis' Afinitor (everolimus) because of doubts over cost-effectiveness.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.